# Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels

> **NCT07353216** · — · RECRUITING · sponsor: **Third Affiliated Hospital, Sun Yat-Sen University** · enrollment: 80 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Ofatumumab

## Key facts

- **NCT ID:** NCT07353216
- **Lead sponsor:** Third Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-01
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07353216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07353216, "Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07353216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*